Comparison of different sources of mesenchymal stem cells: focus on inflammatory bowel disease
Inflammopharmacology · 2024-06 · 32 (3) · 1721-1742
DOI: 10.1007/s10787-024-01468-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Inflammopharmacology, online erschienen am 14.04.2024. Verfasst von Lihao Shi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cheeloo College of Medicine, Shandong University, Jinan, 250012, China. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Mesenchymal Stem Cells, Mesenchymal Stem Cell Transplantation. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 166 Literaturangaben. Gefördert von: Tai Shan Young Scholar Foundation of Shandong Province.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) poses a significant challenge in modern medicine, with conventional treatments limited by efficacy and associated side effects, necessitating innovative therapeutic approaches. Mesenchymal stem cells (MSC) have emerged as promising candidates for IBD treatment due to their immunomodulatory properties and regenerative potential. This thesis aims to explore and compare various sources of MSC and evaluate their efficacy in treating IBD. This study comprehensively analyses MSC derived from multiple sources, including bone marrow, adipose tissue, umbilical cord, and other potential reservoirs. Core elements of this investigation include assessing differences in cell acquisition, immunomodulatory effects, and differentiation capabilities among these MSC sources, as well as comparing their clinical trial outcomes in IBD patients to their therapeutic efficacy in animal models. Through meticulous evaluation and comparative analysis, this thesis aims to elucidate disparities in the efficacy of different MSC sources for IBD treatment, thereby identifying the most promising therapeutic applications. The findings of this study are intended to advance our understanding of MSC biology and offer valuable insights for selecting the most effective MSC sources for personalized IBD therapy. Ultimately, this research endeavor will optimise therapeutic strategies for managing inflammatory bowel disease through the utilization of MSC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.
- Clinical Medical College of Jining Medical University, Jining Medical University, Jining, Shandong, 272000, People's Republic of China.
- Medical Research Center, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, People's Republic of China.
- Department of Burns and Plastic Surgery, Affiliated Hospital of Jining Medical University, Jining, China.
- Department of Gastroenterology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, 272000, People's Republic of China.
- Cheeloo College of Medicine, Shandong University, Jinan, 250012, China. zgx_viola@126.com.
Förderung
- Tai Shan Young Scholar Foundation of Shandong Province
Zitieren
APA
Shi, L., Chen, L., Gao, X., Sun, X., Jin, G., Yang, Y., Shao, Y., Zhu, F., & Zhou, G. (2024). Comparison of different sources of mesenchymal stem cells: focus on inflammatory bowel disease. Inflammopharmacology, 32(3), 1721-1742. https://doi.org/10.1007/s10787-024-01468-1
Vancouver
Shi L, Chen L, Gao X, Sun X, Jin G, Yang Y, et al. Comparison of different sources of mesenchymal stem cells: focus on inflammatory bowel disease. Inflammopharmacology. 2024;32(3):1721-1742. doi:10.1007/s10787-024-01468-1
BibTeX
@article{Shi2024,
author = {Shi, Lihao and Chen, Leilei and Gao, Xizhuang and Sun, Xufan and Jin, Guiyuan and Yang, Yonghong and Shao, Yiming and Zhu, Fengqin and Zhou, Guangxi},
title = {Comparison of different sources of mesenchymal stem cells: focus on inflammatory bowel disease},
journal = {Inflammopharmacology},
year = {2024},
volume = {32},
number = {3},
pages = {1721--1742},
doi = {10.1007/s10787-024-01468-1}
}
EUVIMED